AVO detects masses and calcifications, scores each finding for malignancy, and compares it against the patient's earlier studies — a second read on every screening mammogram, in under three minutes.
The problem
Diagnosed since you opened this page
AVO makes a second read cheap enough to scale — including into mobile units, at the point of screening.
Days to a second read
Scans a radiologist reads in a day. Demand is rising; capacity is not.
Of breast cancers may be missed — higher in dense tissue.
A consistent, fatigue-free second read, in under three minutes.
Reported miss rates, reading volumes and review waits from published screening literature.
Finds suspicious masses and marks them on the image itself, where the radiologist is already looking.
Picks out microcalcification clusters, including in the dense tissue where they are hardest to see.
Gives every finding a probability of malignancy, and the study a cumulative risk score out of ten.
Puts this year's findings beside the previous mammograms, so what changed is visible rather than remembered.
Thousands of screening studies ordered by risk, so the queue reflects urgency instead of arrival.
Radiologist feedback returns to the model, so it keeps improving on the population it actually reads.
A second read in under three minutes, inside the radiology workflow you already have.
9.4/ 10
Who's behind it
An enterprise AI provider. Computer-vision and software engineers, delivering across five countries.
A cancer registry running since 1994. 147,120 neoplasms recorded, over 8,700 patients treated a year. JCI Enterprise re-accredited.
Clinical validation
The clinical study has concluded. The models continue to improve through a feedback loop with the radiologists reviewing them. AVO is being established as its own company, with its own management.
AVO arrives through your PACS, on-premise or in the cloud, to match your regulator — and runs the same way inside a mobile screening unit, where the scan is taken hundreds of miles from the nearest radiologist.
